What's Happening?
Roche has entered into a $1 billion agreement with C4 Therapeutics to develop degrader-antibody conjugates (DACs) for oncology. DACs, similar to antibody-drug conjugates, use catalytic protein degraders
instead of toxins, offering potential benefits like improved specificity and reduced toxicity. Roche will advance DAC candidates through development and commercialization, leveraging its expertise in antibody-drug conjugates.
Why It's Important?
This investment highlights the growing interest in DACs as a promising cancer treatment approach. By combining C4T's degrader technology with Roche's experience in antibody-drug conjugates, the partnership aims to create more effective and safer cancer therapies. The deal reflects the pharmaceutical industry's focus on innovative treatment modalities that can address unmet needs in oncology.
